Contact
searchSearch
HMP Global
Login
Vivek Subbiah, MD
Videos
Tumor-Agnostic Therapies Advance Precision Oncology Through Comprehensive Biomarker Testing
11/04/2026
Vivek Subbiah, MD
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses...
11/04/2026
Oncology
Tiffany Traina, MD
Videos
Optimizing Checkpoint Inhibitor Use Across Early-Stage and Metastatic Triple-Negative Breast Cancer
10/30/2026
Tiffany A. Traina, MD
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses...
10/30/2026
Oncology
Sara Nunnery, MD
Videos
Oral SERDs and ESR1 Mutation Monitoring Reshape Treatment of HR-Positive Metastatic Breast Cancer
10/30/2026
Sara Nunnery, MD, MS
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses...
10/30/2026
Oncology
Rebecca Porter, MD, PhD
Videos
Biomarker-Targeted Therapies Expand Treatment Selection Beyond Platinum Sensitivity in Recurrent Ovarian Cancer
10/30/2026
Rebecca Porter, MD, PhD
Rebecca Porter, MD, discusses evolving treatment strategies for recurrent ovarian cancer, highlighting the expanding role of antibody-drug conjugates, FRα and HER2-biomarker testing, and the importance of integrating molecular...
Rebecca Porter, MD, discusses evolving treatment strategies for recurrent ovarian cancer, highlighting the expanding role of antibody-drug conjugates, FRα and HER2-biomarker testing, and the importance of integrating molecular...
Rebecca Porter, MD, discusses...
10/30/2026
Oncology
Seth Wander, MD, PhD
Videos
Next-Generation Endocrine Therapies Reshape Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer
10/30/2026
Seth Wander MD, PhD
Seth Wander, MD, PhD, discusses advances in endocrine therapy for ER-positive, HER2-negative metastatic breast cancer, highlighting emerging oral SERDs, ESR1 mutation testing, ctDNA-guided treatment strategies from SERENA-6, and novel...
Seth Wander, MD, PhD, discusses advances in endocrine therapy for ER-positive, HER2-negative metastatic breast cancer, highlighting emerging oral SERDs, ESR1 mutation testing, ctDNA-guided treatment strategies from SERENA-6, and novel...
Seth Wander, MD, PhD, discusses...
10/30/2026
Oncology
Olatunji Alese, MD, and Efrat Dotan, MD
Videos
Balancing Promise and Uncertainty With RAS Inhibitors in Pancreatic Cancer
10/14/2026
Olatunji Alese, MD; Efrat Dotan, MD
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat...
10/14/2026
Oncology
Stephanie Berg, DO
Videos
Doublet Therapy Remains Central to First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
10/14/2026
Stephanie Berg, DO
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses...
10/14/2026
Oncology
Atish Choudhury, MD, PhD
Videos
Optimizing Lutetium PSMA Treatment Sequencing in Metastatic Prostate Cancer
10/13/2026
Atish Choudhury, MD, PhD
Atish Choudhury, MD, PhD, discusses the evolving role of lutetium PSMA in metastatic prostate cancer, highlighting evidence supporting earlier treatment, comparisons with taxane chemotherapy, and how PSMA expression, disease burden, toxicity,...
Atish Choudhury, MD, PhD, discusses the evolving role of lutetium PSMA in metastatic prostate cancer, highlighting evidence supporting earlier treatment, comparisons with taxane chemotherapy, and how PSMA expression, disease burden, toxicity,...
Atish Choudhury, MD, PhD,...
10/13/2026
Oncology
Yelena Janjigian, MD
Videos
New HER2-Directed Therapies Reshape First-Line Treatment of Gastroesophageal Adenocarcinoma
10/08/2026
Yelena Y. Janjigian, MD
Yelena Janjigian, MD, discusses the evolving first-line treatment landscape for HER2-positive gastroesophageal adenocarcinoma, including newly approved zanidatamab-based regimens, established trastuzumab-based therapy, biomarker-guided...
Yelena Janjigian, MD, discusses the evolving first-line treatment landscape for HER2-positive gastroesophageal adenocarcinoma, including newly approved zanidatamab-based regimens, established trastuzumab-based therapy, biomarker-guided...
Yelena Janjigian, MD, discusses...
10/08/2026
Oncology
Scott Tagawa, MD
Videos
Targeted Radionuclide Therapy Moves Earlier Across the Cancer Treatment Continuum
10/08/2026
Scott Tagawa, MD
Scott Tagawa, MD, discusses the expanding role of targeted radionuclide therapy across oncology, highlighting theranostic imaging for patient selection, the movement of radiopharmaceuticals into earlier treatment settings, and the...
Scott Tagawa, MD, discusses the expanding role of targeted radionuclide therapy across oncology, highlighting theranostic imaging for patient selection, the movement of radiopharmaceuticals into earlier treatment settings, and the...
Scott Tagawa, MD, discusses the...
10/08/2026
Oncology
Cathy Eng, MD
Videos
Advances in the Metastatic Anal Carcinoma Treatment Landscape
04/01/2026
Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, discusses recent updates in anal carcinoma, highlighting rising incidence and ongoing unmet needs in advanced disease.
Cathy Eng, MD, discusses recent updates in anal carcinoma, highlighting rising incidence and ongoing unmet needs in advanced disease.
Cathy Eng, MD, discusses recent...
04/01/2026
Oncology
Daniel Rosas, MD
Videos
Rethinking the Role of Second-Line Chemotherapy in Advanced Lung Cancer
03/20/2026
Daniel Rosas, MD
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses...
03/20/2026
Oncology
Sarah Premji, MD
Videos
Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/20/2026
Sarah Premji, MD
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses...
03/20/2026
Oncology
Edward Garon, MD
Videos
Biomarkers as the Foundation of Tumor-Agnostic Therapy
03/19/2026
Edward B. Garon, MD, MS
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the...
03/19/2026
Oncology
Adam Brufsky, MD, PhD
Videos
Evaluating ctDNA-Guided Therapy in Early-Stage Breast Cancer
03/19/2026
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses...
03/19/2026
Oncology
Angeles Secord, MD
Videos
Refining HRD-Guided PARP Inhibitor Use in Advanced Ovarian Cancer
03/19/2026
Angeles Secord, MD
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses...
03/19/2026
Oncology
Midun Mala, MD
Videos
Evaluating Adjuvant HAI Pump Therapy in Patients With Resected Colorectal Liver Metastases
03/19/2026
Midhun Malla, MD, MS
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use...
03/19/2026
Oncology
Arnab Basu, MD
Videos
Emerging Bladder Preservation Strategies for Patients With Muscle-Invasive Bladder Cancer
03/19/2026
Arnab Basu, MD
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses...
03/19/2026
Oncology
Scott Tagawa, MD
Videos
Theranostics Advances in Solid Tumors
03/19/2026
Scott Tagawa, MD
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the...
03/19/2026
Oncology
Yuan Yuan, MD, PhD
Videos
Expanding the Role of Immunotherapy in Triple-Negative Breast Cancer
03/18/2026
Yuan Yuan, MD, PhD
Yuan Yuan, MD, PhD, discusses whether all patients with triple-negative breast cancer should receive immunotherapy.
Yuan Yuan, MD, PhD, discusses whether all patients with triple-negative breast cancer should receive immunotherapy.
Yuan Yuan, MD, PhD, discusses...
03/18/2026
Oncology
Seth Wander, MD, PhD
Videos
Evaluating Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/18/2026
Seth Wander MD, PhD
Seth Wander, MD, PhD, discusses whether emerging oral SERDs differ meaningfully in HR-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses whether emerging oral SERDs differ meaningfully in HR-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses...
03/18/2026
Oncology
Rutika Mehta, MD
Videos
Considerations for Immunotherapy Rechallenge in Esophageal and Gastric Cancers
03/17/2026
Rutika Mehta, MD, MPH
Rutika Mehta, MD, discusses whether immunotherapy rechallenge should be considered for patients with esophageal and gastric cancers.
Rutika Mehta, MD, discusses whether immunotherapy rechallenge should be considered for patients with esophageal and gastric cancers.
Rutika Mehta, MD, discusses...
03/17/2026
Oncology
Rebecca Porter, MD, PhD
Videos
Rethinking Treatment Strategies in Recurrent Ovarian Cancer
03/17/2026
Rebecca Porter, MD, PhD
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD,...
03/17/2026
Oncology
Estelamari Rodriguez, MD
Videos
Perioperative Immunotherapy for Patients With Resectable Non-Small Cell Lung Cancer
03/15/2026
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD,...
03/15/2026
Oncology
Joshua Linscott, MD
Videos
Consolidation Therapy After Clinical Complete Response in Muscle-Invasive Bladder Cancer
03/15/2026
Joshua Linscott, MD, PhD
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD,...
03/15/2026
Oncology
Kelsey Pan, MD
Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
Kelsey Pan, MD
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses...
03/14/2026
Oncology
Luis Raez, MD
Videos
Second-Line Treatment Options in Metastatic NSCLC
03/14/2026
Luis Raez, MD
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current...
03/14/2026
Oncology
Tian Zhang, MD
Videos
Optimizing First-Line Immunotherapy in Metastatic Renal Cell Carcinoma
03/14/2026
Tian Zhang, MD
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses...
03/14/2026
Oncology
Guru Sonpavde, MD
Videos
ctDNA Guided Adjuvant Therapy for Patients With Muscle-Invasive Bladder Cancer
03/14/2026
Guru Sonpavde, MD
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses...
03/14/2026
Oncology
Melinda Telli, MD
Videos
Immunotherapy for All Patients With Triple-Negative Breast Cancer
03/14/2026
Melinda Telli, MD
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses...
03/14/2026
Oncology
Debate driven oncology education meets the most urgent GU decision points, from biomarker strategy to treatment sequencing in prostate, renal, and bladder cancers.
Blog
OLN Great Debates 2026: Genitourinary Cancers, New Leadership Join the Spotlight
02/25/2026
Matthew Galsky, MD
Debate driven oncology education meets the most urgent GU decision points, from biomarker strategy to treatment sequencing in prostate, renal, and bladder cancers.
Debate driven oncology education meets the most urgent GU decision points, from biomarker strategy to treatment sequencing in prostate, renal, and bladder cancers.
Debate driven oncology education...
02/25/2026
Oncology
Kelly E. McCann, MD, PhD
News
OLN Great Debates: Navigating Evolving Evidence and Treatment Decisions in Breast Oncology
02/17/2026
Kelly McCann, MD, PhD
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast...
02/17/2026
Oncology
Nivedh Paluvoi, MD
Videos
Evaluating Biomarker-Based Approaches to Colorectal Cancer Screening
10/23/2025
Nivedh Paluvoi, MD, discusses the evolving landscape of colorectal cancer screening, emphasizing biomarker-based testing as an emerging alternative to traditional methods.
Nivedh Paluvoi, MD, discusses the evolving landscape of colorectal cancer screening, emphasizing biomarker-based testing as an emerging alternative to traditional methods.
Nivedh Paluvoi, MD, discusses...
10/23/2025
Oncology
Reid Ness, MD, MPH
Videos
The Role of Colonoscopy in the Modern Era of Colorectal Cancer Screening
10/23/2025
Reid Ness, MD
Reid Ness, MD, MPH, discusses the role colonoscopy has in the detection and prevention of colorectal cancer in the modern screening era.
Reid Ness, MD, MPH, discusses the role colonoscopy has in the detection and prevention of colorectal cancer in the modern screening era.
Reid Ness, MD, MPH, discusses...
10/23/2025
Oncology
Seth Wander, MD, PhD
Videos
Earlier Use of Next-Generation Anti-Estrogen Agents in Breast Cancer
10/23/2025
Seth Wander, MD
Seth Wander, MD, PhD, discusses the evolving role of next-generation oral anti-estrogen agents in ER-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses the evolving role of next-generation oral anti-estrogen agents in ER-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses...
10/23/2025
Oncology
Sarah Premji, MD
Videos
ctDNA to Guide Treatment Decisions in ER-Positive Metastatic Breast Cancer
10/23/2025
Sarah Premji, MD, examines the role of ctDNA in guiding treatment changes for patients with ER-positive metastatic breast cancer. 
Sarah Premji, MD, examines the role of ctDNA in guiding treatment changes for patients with ER-positive metastatic breast cancer. 
Sarah Premji, MD, examines the...
10/23/2025
Oncology
Jennifer Scalici, MD
Videos
Standard Platinum-Based Chemo Following PARPi Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer
10/23/2025
Jennifer Scalici, MD, explores the evolving role of platinum therapy following PARP inhibitor progression in the platinum-sensitive setting.
Jennifer Scalici, MD, explores the evolving role of platinum therapy following PARP inhibitor progression in the platinum-sensitive setting.
Jennifer Scalici, MD, explores...
10/23/2025
Oncology
Rutika Mehta, MD, MPH
Videos
Targeted Approach to Biomarker Testing for Patients With Upper Gastrointestinal Malignancies
10/22/2025
Rutika Mehta, MD, MPH
Rutika Mehta, MD, MPH, discusses targeted approaches to biomarker testing for patients with upper gastrointestinal malignancies.
Rutika Mehta, MD, MPH, discusses targeted approaches to biomarker testing for patients with upper gastrointestinal malignancies.
Rutika Mehta, MD, MPH, discusses...
10/22/2025
Oncology
Nataliya Uboha, MD, PhD
Videos
Adjuvant Treatment of Patients With Early-Stage Gastroesophageal Carcinomas
10/22/2025
Nataliya Uboha, MD, PhD
Nataliya Uboha, MD, PhD, discusses adjuvant treatment of patients with early-stage gastroesophageal adenocarcinomas.
Nataliya Uboha, MD, PhD, discusses adjuvant treatment of patients with early-stage gastroesophageal adenocarcinomas.
Nataliya Uboha, MD, PhD,...
10/22/2025
Oncology
Luis Raez, MD, Memorial Cancer Institute
Videos
CTLA-4 Inhibition for Lung Cancer
09/19/2025
Luis Raez, MD
Luis Raez, MD, discusses the use of CTLA-4 inhibitor for patients with lung cancer.
Luis Raez, MD, discusses the use of CTLA-4 inhibitor for patients with lung cancer.
Luis Raez, MD, discusses the use...
09/19/2025
Oncology
Kelly McCann, MD, PhD, UCLA
Videos
Sequencing Antibody-Drug Conjugates Among Patients With Breast Cancer
09/18/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses...
09/18/2025
Oncology
Heather Moore, CPP, PharmD, Duke Cancer Center
Videos
Managing Adverse Events for Patients With Breast Cancer
09/17/2025
Heather Moore, PharmD
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD,...
09/17/2025
Oncology
Drew Moghanaki, MD, MPH, University of California, Los Angeles
Videos
Radiation for Patients With Stage 3 Lung Cancer
09/17/2025
Drew Moghanaki, MD, MPH
Drew Moghanaki, MD, MPH, University of California, Los Angeles, discusses whether patients with resectable lung cancer should be offered a chemo-radiation approach.
Drew Moghanaki, MD, MPH, University of California, Los Angeles, discusses whether patients with resectable lung cancer should be offered a chemo-radiation approach.
Drew Moghanaki, MD, MPH,...
09/17/2025
Oncology
Rutika Mehta, MD, MPH, Weill Cornell Medicine
Videos
Optimizing Supportive Care for Patients With GI Cancers
09/17/2025
Rutika Mehta, MD, MPH
Rutika Mehta, MD, MPH, discusses how to optimize supportive care for patients with gastrointestinal cancers.
Rutika Mehta, MD, MPH, discusses how to optimize supportive care for patients with gastrointestinal cancers.
Rutika Mehta, MD, MPH, discusses...
09/17/2025
Oncology
Olatunji Alese, MD, Winship Cancer Center
Videos
Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma
09/17/2025
O. Alese
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses...
09/17/2025
Oncology
Sameera Kumar, MD
Conference Coverage
Radiation for Patients With Stage 3 Non-Small Cell Lung Cancer
03/27/2025
Sameera Kumar, MD
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights...
03/27/2025
Oncology
William Grady, MD
Conference Coverage
Biomarker-Based Testing vs Colonoscopy for Colorectal Cancer Screening
03/27/2025
William Grady, MD
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares...
03/27/2025
Oncology
Estelamari Rodriguez, MD, MPH
Conference Coverage
First-Line CTLA-4 Inhibitors for Patients With Non-Small Cell Lung Cancer
03/27/2025
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, MPH, assesses the potential of CTLA-4 inhibitors in the first-line setting for patients with non-small cell lung cancer.
Estelamari Rodriguez, MD, MPH, assesses the potential of CTLA-4 inhibitors in the first-line setting for patients with non-small cell lung cancer.
Estelamari Rodriguez, MD, MPH,...
03/27/2025
Oncology
Deborah Doroshow, MD, PhD
Conference Coverage
Immunotherapy for Patients With Small Cell Lung Cancer
03/27/2025
Deborah Doroshow, MD, PhD
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD,...
03/27/2025
Oncology
Reid Ness, MD, MPH
Conference Coverage
Assessing Evidence for Colonoscopy as a Primary Screening Tool
03/27/2025
Reid Ness, MD
Reid Ness, MD, MPH, discusses the nordICC trial, which assessed the efficacy of using colonoscopy as a primary screening tool.
Reid Ness, MD, MPH, discusses the nordICC trial, which assessed the efficacy of using colonoscopy as a primary screening tool.
Reid Ness, MD, MPH, discusses...
03/27/2025
Oncology
Vivek Subbiah, MD
Conference Coverage
Tumor Agnostic Therapies for Patients With Solid Tumors
03/27/2025
Vivek Subbiah, MD
Vivek Subbiah, MD, discusses advances in tumor agnostic therapies and explores how these therapies can shift the treatment landscape for patients with solid tumors.
Vivek Subbiah, MD, discusses advances in tumor agnostic therapies and explores how these therapies can shift the treatment landscape for patients with solid tumors.
Vivek Subbiah, MD, discusses...
03/27/2025
Oncology
Reid Ness, MD, MPH
Conference Coverage
Colonoscopy for the Detection of Colorectal Cancer
03/27/2025
Reid Ness, MD
Reid Ness, MD, MPH, argues that colonoscopy is superior compared to biomarker-based testing for the detection of colorectal cancer.
Reid Ness, MD, MPH, argues that colonoscopy is superior compared to biomarker-based testing for the detection of colorectal cancer.
Reid Ness, MD, MPH, argues that...
03/27/2025
Oncology
Shipra Gandhi, MD, Winship Cancer Institute
Videos
An Argument Against Earlier Novel Endocrine Backbones for Breast Cancer
03/27/2025
Shipra Gandhi, MD
Shipra Gandhi, MD, makes the case against moving novel endocrine backbones to earlier lines of therapy in breast cancer.
Shipra Gandhi, MD, makes the case against moving novel endocrine backbones to earlier lines of therapy in breast cancer.
Shipra Gandhi, MD, makes the...
03/27/2025
Oncology
Raghav Sundar, MD, PhD, Yale Cancer Center
Videos
Integrating Anatomy Into Treatment Decisions for Gastrointestinal Cancers
03/27/2025
Raghav Sundar, MD
Raghav Sundar, MD, PhD, discusses the importance of considering tumor biology and anatomic site when determining treatments for patients with gastrointestinal cancers.
Raghav Sundar, MD, PhD, discusses the importance of considering tumor biology and anatomic site when determining treatments for patients with gastrointestinal cancers.
Raghav Sundar, MD, PhD,...
03/27/2025
Oncology
Seth Wander, MD, PhD
Conference Coverage
Earlier Use of Novel Endocrine Backbones for Patients With HR-Positive Breast Cancer
03/26/2025
Seth Wander, MD
Seth Wander, MD, PhD, discusses key considerations for moving novel endocrine backbones into earlier lines of therapy for patients with hormone receptor-positive breast cancer.
Seth Wander, MD, PhD, discusses key considerations for moving novel endocrine backbones into earlier lines of therapy for patients with hormone receptor-positive breast cancer.
Seth Wander, MD, PhD, discusses...
03/26/2025
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Role of Upfront Liquid Biopsies in the Diagnosis of Lung Cancer
03/26/2025
Christian Rolfo, MD, PhD
Christian Rolfo, MD, explores the evidence supporting the use of upfront liquid biopsies in the diagnosis of lung cancer.
Christian Rolfo, MD, explores the evidence supporting the use of upfront liquid biopsies in the diagnosis of lung cancer.
Christian Rolfo, MD, explores...
03/26/2025
Oncology
Richard Finn, MD
Conference Coverage
Dual Checkpoint Inhibition for Patients With Advanced Hepatocellular Carcinoma
03/25/2025
Richard Finn, MD, assesses the use of dual checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
Richard Finn, MD, assesses the use of dual checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
Richard Finn, MD, assesses the...
03/25/2025
Oncology
James Harding, MD
Conference Coverage
Combination VEGF and Immune Checkpoint Inhibitors as a First-Line Option for Patients With Advanced Hepatocellular Carcinoma
03/25/2025
James J. Harding
James Harding, MD, discusses advantages associated with combining VEGF inhibitors and immune checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
James Harding, MD, discusses advantages associated with combining VEGF inhibitors and immune checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
James Harding, MD, discusses...
03/25/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Sequential Use of Antibody-Drug Conjugates for Patients With Breast Cancer
03/25/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD,...
03/25/2025
Oncology
Heather Moore, PharmD, BCOP, CPP, Duke Cancer Center
Videos
Managing Adverse Events in Breast Cancer Treatment
03/25/2025
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP,...
03/25/2025
Oncology
Jamie Chaft, MD
Conference Coverage
Surgery vs Radiation for Patients With Stage 3 Non-Small Cell Lung Cancer
03/25/2025
Jamie Chaft, MD
Jamie Chaft, MD, highlights the role of surgical resection in the treatment of patients with stage 3 non-small cell lung cancer.
Jamie Chaft, MD, highlights the role of surgical resection in the treatment of patients with stage 3 non-small cell lung cancer.
Jamie Chaft, MD, highlights the...
03/25/2025
Oncology
Don Dizon, MD
Conference Coverage
Impact of Anticancer Treatment on Sexual Function and Intimacy
03/22/2025
Don S. Dizon, MD
Don Dizon, MD, explores the relationship between anticancer treatment-related sexual side effects and intimacy among patients undergoing cancer treatment.
Don Dizon, MD, explores the relationship between anticancer treatment-related sexual side effects and intimacy among patients undergoing cancer treatment.
Don Dizon, MD, explores the...
03/22/2025
Oncology
News
HMP Global’s Great Debates in Solid Tumors events deliver best of three popular oncology conferences
03/19/2025
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three...
03/19/2025
Oncology

About

About

Join us for the first-ever Great Debates in Solid Tumors, where three established oncology programs come together in one comprehensive event.

This unique event offers exclusive access to a distinguished faculty presenting the latest clinical data and evolving standards across the following treatment areas: gastrointestinal, women’s, and lung cancers. Engage in rigorous debates and case-based discussions, designed to deepen your understanding of evidence-based approaches, while networking with colleagues equally committed to advancing patient outcomes. Don’t miss this opportunity to connect, learn, and lead in solid tumor care.
 

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use